Imbruvica lassoes CLL indication

Share this article:

The FDA has expanded the indication for Johnson & Johnson and Pharmacyclics' Imbruvica to include chronic lymphocytic leukemia patients who have a chromosome 17 deletion which is associated with a poor response to standard CLL treatments.

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February. The FDA approved Imbruvica for the rare, aggressive cancer mantle cell lymphoma in November 2013.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters